Shanghai HeartCare Reports Shareholder Turnout and Voting Base for 2026 First EGM and Class Meetings

Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has issued an announcement.

Shanghai HeartCare Medical Technology Corporation Limited held its 2026 first extraordinary general meeting (EGM), along with separate class meetings for H shareholders and unlisted shareholders, on 16 January 2026 in Shanghai, with all directors attending either in person or electronically. The meetings were duly convened under PRC company law and the company’s articles, with voting share figures adjusted to exclude unvested incentive shares and treasury shares, resulting in 37,461,408 shares eligible to vote at the EGM and strong class meeting participation (34.30% of H shares and 79.86% of unlisted shares), underscoring robust shareholder engagement and procedural compliance in the company’s governance process.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$71.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H

Shanghai HeartCare Medical Technology Corporation Limited is a PRC-incorporated medical technology company listed in Hong Kong (Stock Code: 6609). It operates in the medical devices/medtech industry, focusing on innovative cardiovascular and neurovascular interventional products and related technologies for both domestic and international markets.

Average Trading Volume: 67,134

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.41B

See more insights into 6609 stock on TipRanks’ Stock Analysis page.